Impact of Clinical Practice Gaps in NSCLC

Four years ago, our first Clinical Practice Gaps Analysis revealed a headline that shook the industry.

Our first in-depth study carried out in conjunction with the Personalized Medicine Coalition regarding the use of diagnostic testing for lung cancer patients in the US identified that over half of patients are not receiving the right treatment for them.

Highlights of the paper:

64.4% of lung cancer patients in the US do not receive the right treatment for them
There are 7 “gaps” in which patients are being lost in their testing journey
18% of patients do not receive treatment due to inconclusive or false negative diagnostic results
29% of patients were also lost due to a gap in clinicians not prescribing the targeted or immuno-oncology therapy the patient could have benefitted from despite the diagnostics being carried out correctly
There exists a huge opportunity for stakeholders within the precision medicine industry to take action and enable patients to receive the treatment they deserve